Skip to main content
. 2021 Jun 2;12(4):964–972. doi: 10.1002/jcsm.12719

Figure 1.

Figure 1

Overall and cause‐specific mortality by NAFLD and sarcopenic status. Cumulative survivals according to (A) overall mortality in subjects with (solid black line) and without (dashed black line) NAFLD; and (B) overall, (C) CVD‐related, and (D) cancer‐related mortality by the presence of either NAFLD and/or sarcopenia for median 6.8 years of follow‐up were analysed using Cox proportional hazards analysis. (1) No NAFLD and no sarcopenia (dashed grey line), (2) no NAFLD but sarcopenia (solid grey line), (3) NAFLD without sarcopenia (dashed black line), and (4) NAFLD with sarcopenia (solid black line) (unweighted N = 28 060; overall mortality, 2.5% (SE, 0.1%); CVD‐related mortality, 0.5% (SE, 0.0%); cancer‐related mortality, 0.9% (SE, 0.1%)). Hazard ratios (95% confidence intervals) were calculated after adjustment for age, sex, BMI, hypertension, dyslipidemia, smoking, and diabetes mellitus for Figure 1A (Model 3 in Table 2) or further adjustment for chronic kidney disease, vitamin D, dyslipidaemia medication, and advanced fibrosis for Figure 1B–D (Model 4 in Table 3 or Supporting Information, Table S5).